Skip to Main Content

Paper Details

Cooperative Genomic Lesions in HRAS-Mutant Cancers Predict Resistance to Farnesyltransferase Inhibitors.
Res Sq
0
2023
-, - vs - and -mutant cancers, -mutant lineages, -mutant tumors, FTI, Farnesyltransferase, HRAS, HRAS-Mutant Cancers, Kras, MAPK, MEFs, MEK, PI3K, RASless, RTK, cancer, embryonic fibroblasts, farnesyltransferase, mouse, tipifarnib, transfected MEFs, tumors
Author NameAffiliation
Walid K ChatilaMemorial Sloan-Kettering Cancer Center.
Alan L HoMemorial Sloan-Kettering Cancer Center.
Nikolaus SchultzCenter for Molecular Oncology, Memorial Sloan Kettering Cancer Center.
Nikolaus SchultzCenter for Molecular Oncology, Memorial Sloan Kettering Cancer Center.
  • 1 - 4

Datasets

Release 1.2